Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...
UBS analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $70 to $40.
JP Morgan analyst Jessica Fye maintains Moderna (NASDAQ:MRNA) with a Underweight and lowers the price target from $26 to $25.
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and ...
Citigroup analyst Geoff Meacham maintains Moderna (NASDAQ:MRNA) with a Neutral and lowers the price target from $30 to $28.
Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, ...
DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.
U.S. stocks rise on Monday, with the Dow up 500+ points. Moderna and Cleveland-Cliffs report gains. Most S&P sectors close ...
Wall Street rallied to start the week, with small-cap stocks and regional banks rebounding sharply after last week's credit...
